glp 1 news GLP-1 receptor agonists show promise in treating substance use disorders Science's 2023 Breakthrough: GLP-1 Agonists

Tirzepatides dual-action mechanism targets both the GLP-1 and GIP receptors, making it a powerful tool in diabetes management

GLP-1 receptor activation inhibits the activation of hepatic Kupffer cells and infiltrating macrophages, leading to decreased production of pro-inflammatory cytokines such as TNF- and IL-1, thereby attenuating hepatic inflammation (44)

In early 2024, well find out how Mounjaro stacks up against this

Build sustainable momentum with GLP-1 microdosing A lower-dose approach can be a smart way to start or restart GLP-1 therapy

Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides

8.6 Last Word The 2025 warning letter evidence supports a clear and defensible conclusion: computerized system data integrity failures under 21 CFR 211.68(b) are are global in distribution and common in mechanism